Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML
N/A
30 Years
Both
Leukemia
Trial Information
Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML
OBJECTIVES:
- Investigate whether changes in prosurvival signaling occur by comparing activation of
the signal transducer and activator of transcription-3 (Stat3) and Stat5 pathways in
paired diagnostic and relapse samples.
- Investigate changes in leukemia cell responses to extrinsic cues from the environment
change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance.
OUTLINE: Cryopreserved samples are analyzed for Stat3 and Stat5 expression by flow cytometry
and in vitro chemotherapy sensitivity.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Paired diagnostic and relapsed cryopreserved samples from patients with acute myeloid
leukemia
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Changes in Stat3 and Stat5 in paired diagnostic and relapsed AML samples
Safety Issue:
No
Principal Investigator
Michele S. Redell, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Texas Children's Cancer Center
Authority:
United States: Federal Government
Study ID:
CDR0000709080
NCT ID:
NCT01419496
Start Date:
September 2011
Completion Date:
Related Keywords:
- Leukemia
- recurrent adult acute myeloid leukemia
- recurrent childhood acute myeloid leukemia
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(15;17)(q22;q12)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- adult acute myeloid leukemia with del(5q)
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
